Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. Here, CD7 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.